BLRX and YP2 Related Headlines
Go Back- BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
- BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- BioLineRx begins phase 1/2a trial of GLIX1 for glioblastoma treatment
- BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
- BioLineRx to Report 2025 Annual Results on March 23, 2026
BLRX and YP2 Related Press Releases
Go Back- BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
- BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
- BioLineRx to Report 2025 Annual Results on March 23, 2026
